Trial · NCT07910305
Transcranial Magnetic Stimulation (TMS) for Autism Spectrum Disorder
NCT07910305, Not applicable, Not yet recruiting, Sir Run Run Shaw Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Transcranial Magnetic Stimulation (TMS) for Autism Spectrum Disorder. Trials, record NCT07910305. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07910305
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Transcranial Magnetic Stimulation (TMS) for Autism Spectrum Disorder
- NCT number
- NCT07910305
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 120 participants, estimated
- Lead sponsor
- Sir Run Run Shaw Hospital
- Conditions
- Autism Spectrum Disorder, TMS
- Interventions
- Individualized Cerebellar-Targeted Repetitive Transcranial Magnetic Stimulation
- First posted
- 2026-11-02
- Last updated
- 2026-11-03
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Social Responsiveness Scale (SRS) Total Score From Baseline to Week 2 | Baseline and Week 2 | The Social Responsiveness Scale (SRS) is a caregiver-reported questionnaire used to assess social communication and interaction difficulties in individuals with autism spectrum disorder. The scale consists of 65 items, each rated from 0 to 3, with a total score ranging from 0 to 195. Higher scores indicate greater severity of social impairment. The primary outcome is the change in SRS total score from baseline to week 2 following individualized cerebellar-targeted repetitive transcranial magnetic stimulation (rTMS). |
| Secondary | Change in Social Responsiveness Scale (SRS) Total Score From Baseline to Week 12 | Baseline and Week 12 | The Social Responsiveness Scale (SRS) consists of 65 items rated from 0 to 3, with a total score ranging from 0 to 195. Higher scores indicate greater severity of social impairment. This outcome measures the change in SRS total score from baseline to week 12 to evaluate the persistence of treatment-related changes in social functioning. |
| Secondary | Change in Repetitive Behavior Scale-Revised (RBS-R) Total Score From Baseline | Baseline, Week 2, and Week 12 | The Repetitive Behavior Scale-Revised (RBS-R) is a caregiver-reported questionnaire used to assess restricted and repetitive behaviors in individuals with autism spectrum disorder. It consists of 43 items, each rated from 0 to 3, with a total score ranging from 0 to 129. Higher scores indicate more severe repetitive behaviors. Changes in RBS-R total scores from baseline will be assessed following rTMS treatment. |
| Secondary | Change in Strengths and Difficulties Questionnaire (SDQ) Total Difficulties Score From Baseline | Baseline, Week 2, and Week 12 | The Strengths and Difficulties Questionnaire (SDQ) is a caregiver-reported questionnaire used to assess emotional and behavioral difficulties in children and adolescents. It consists of 25 items across five subscales: emotional symptoms, conduct problems, hyperactivity/inattention, peer relationship problems, and prosocial behavior. The total difficulties score ranges from 0 to 40 and is calculated by summing the first four subscales. Higher scores indicate greater emotional and behavioral difficulties. Changes from baseline will be evaluated at weeks 2 and 12. |
| Secondary | Change in Cerebellar Functional Connectivity Assessed by Resting-State Functional MRI | Baseline, Week 2, and Week 12 | Resting-state functional magnetic resonance imaging (rs-fMRI) will be performed to investigate changes in functional connectivity following individualized cerebellar-targeted rTMS. Functional connectivity between the cerebellum and cortical regions, particularly the medial prefrontal cortex, will be analyzed at baseline, week 2, and week 12. Changes in functional connectivity will be evaluated to explore potential neural mechanisms associated with treatment-related clinical improvements. |
| Secondary | Genetic Variants Identified Through Peripheral Blood Genotyping | Baseline | Peripheral blood samples will be collected once at baseline for genetic testing and genotyping. Approximately 18 mL of blood will be collected from each participant in three tubes (approximately 6 mL per tube). Genetic analysis will be performed to identify and characterize genetic variants among participants with autism spectrum disorder (ASD). The results will be summarized according to the genetic variants and genotypes identified. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07910305
GET https://conductscience.org/api/trials/v1/NCT07910305/registered